一年一度的临床肿瘤学界奥林匹克盛会——美国临床肿瘤学会（ASCO）年会将于当地时间6月2～6日在芝加哥举行。日前，ASCO会议官网公布了此次年会的日程和摘要题目。结直肠癌领域多项重磅研究即将公布，本文带您提前速览摘要题目。
编者按：一年一度的临床肿瘤学界奥林匹克盛会——美国临床肿瘤学会（ASCO）年会将于当地时间6月2～6日在芝加哥举行。日前，ASCO会议官网公布了此次年会的日程和摘要题目。结直肠癌领域多项重磅研究即将公布，本文带您提前速览摘要题目。
01
口头摘要专场
（Oral Abstract Session）
Abstract:3500
FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer(mCRC):Updated and overall survival results of the phase II randomized AtezoTRIBE study.
FOLFOXIRI联合贝伐珠单抗和阿替利珠单抗作为不可切除转移性结直肠癌的前期治疗：Ⅱ期随机AtezoTRIBE研究的更新和总生存结果
Presenter:Carlotta Antoniotti，MD，PhD|Department of Translational Research and New Technologies in Medicine and Surgery，University of Pisa&Unit of Medical Oncology 2，Azienda Ospedaliero-Universitaria Pisana
Abstract:3501
Trastuzumab deruxtecan(T-DXd)in patients(pts)with HER2-overexpressing/amplified(HER2+)metastatic colorectal cancer(mCRC):Primary results from the multicenter，randomized，phase 2 DESTINY-CRC02 study.
Trastuzumab deruxtecan（T-DXd）治疗HER2过表达/扩增（HER2+）转移性结直肠癌（mCRC）患者（患者）：多中心、随机、2期DESTINY-CRC02研究的主要结果
Presenter:Kanwal Pratap Singh Raghav，MBBS|The University of Texas MD Anderson Cancer Center
Abstract:LBA3503
Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer:The NeoCol trial.
比较局部晚期结肠癌患者新辅助化疗和标准治疗疗效的Ⅲ期随机临床试验：NeoCol试验
Presenter:Lars Henrik Jensen，MD，PhD|Danish Colorectal Cancer Center South，University Hospital of Southern Denmark，Vejle Hospital
Abstract:LBA3504
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer:7-year results of PRODIGE 23 phase III trial，a UNICANCER GI trial.
局部晚期直肠癌患者进行mFOLFIRINOX的全程新辅助治疗vs.术前放化疗：PRODIGE 23Ⅲ期试验的7年结果，UNICANCER GI试验
Presenter:Thierry Conroy，MD|Institut de Cancérologie de Lorraine
Abstract:3505
Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer:A multicenter，randomized phase III trial.
新辅助mFOLFOX6联合或不联合放疗vs.氟尿嘧啶加放疗治疗局部晚期直肠癌的长期结果：一项多中心、随机Ⅲ期临床试验
Presenter:邓艳红教授中山大学附属第六医院
Abstract:3506
NeoRAS wild-type metastatic colorectal cancer in the SCRUM-Japan GOZILA study.
SCRUM-Japan GOZILA研究中的NeoRAS野生型转移性结直肠癌
Presenter:Hiroki Osumi，MD，PhD|Department of Gastroenterological Chemotherapy，Cancer Institute Hospital of Japanese Foundation for Cancer Research
Abstract:3507
Phase III FIRE-4 study(AIO KRK-0114):Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.
Ⅲ期FIRE-4研究（AIO KRK-0114）：基线液体活检结果对RAS-WT mCRC患者FOLFIRI/西妥昔单抗一线治疗疗效的影响
Presenter:Sebastian Stintzing，MD|Medical Department，Division of Hematology，Oncology，and Cancer Immunology(CCM)，CharitéUniversitätsmedizin Berlin
Abstract:3508
Efficacy of panitumumab in patients with left-sided disease，MSS/MSI-L，and RAS/BRAF WT:A biomarker study of the phase III PARADIGM trial.
帕尼单抗对左半、MSS/MSI-L和RAS/BRAF WT患者的疗效：Ⅲ期PARADIGM试验的生物标志物研究
Presenter:Kentaro Yamazaki，MD，PhD|Division of Gastrointestinal Oncology，Shizuoka Cancer Center
02
壁报交流专场
（Poster Discussion Session）
Abstract:3512|Poster Bd#:212
Overall survival results for trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab:Results from the phase 3 SOLSTICE study.
曲氟尿苷替匹嘧啶联合贝伐珠单抗vs.卡培他滨联合贝伐珠单抗的总生存结果：来自Ⅲ期SOLSTICE研究的结果
Presenter:Thierry Andre，MD|Hôpital Saint-Antoine
Abstract:3513|Poster Bd#:213
Sotorasib(Soto)plus panitumumab(Pmab)and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer(mCRC):CodeBreaK 101 phase 1b safety and efficacy.
Sotorasib（Soto）联合帕尼单抗（Pmab）和FOLFIRI治疗KRAS G12C突变的转移性结直肠癌（mCRC）：CodeBreaK 101 1b期的安全性和有效性
Presenter:David S.Hong，MD|University of Texas MD Anderson Cancer Center
Abstract:3514|Poster Bd#:214
Phase 1 study of WNT pathway Porcupine inhibitor CGX1321 and phase 1b study of CGX1321+pembrolizumab(pembro)in patients(pts)with advanced gastrointestinal(GI)tumors.
WNT通路Porcupine抑制剂CGX1321的1期研究和CGX1321+帕博利珠单抗（pembro）治疗晚期胃肠道（GI）肿瘤患者的1b期研究
Presenter:Marios Giannakis，MD，PhD|Dana-Farber Cancer Institute
Abstract:3515|Poster Bd#:215
Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence:A multicenter randomized phase II trial(PRODIGE 43-PACHA-01).
肝复发高危患者结直肠肝转移瘤切除术后肝动脉化疗：一项多中心随机Ⅱ期临床试验（PRODIGE 43-PACHA-01）
Presenter:Maximiliano Gelli，MD，PhD|Gustave Roussy
Abstract:3516|Poster Bd#:216
Adjuvant systemic chemotherapy with or without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastases resection(HARVEST):A prospective，randomized controlled trial.
结直肠癌肝转移切除术患者辅助全身化疗联合或不联合肝动脉氟尿嘧啶灌注：前瞻性、随机对照HARVEST试验
Presenter:李宇红教授中山大学肿瘤防治中心
Abstract:3517|Poster Bd#:217
Upfront palliative resection of primary tumor versus no resection in patients with synchronous metastatic colorectal cancer:The randomized phase 3 CAIRO4 study of the Dutch Colorectal Cancer Group(DCCG).
同步转移性结直肠癌患者原发性肿瘤前期姑息性切除vs.不切除：荷兰结直肠癌组（DCCG）的随机Ⅲ期CAIRO4期研究
Presenter:Miriam Koopman，MD，PhD|Department of Medical Oncology，University Medical Center Utrecht，Utrecht University
Abstract:3518|Poster Bd#:218
15-month safety and efficacy data after intraperitoneal treatment with 224Radium-labelled microparticles after CRS-HIPEC for peritoneal metastasis from colorectal cancer.
CRS-HIPEC治疗结直肠癌腹膜转移后，224-镭标记微粒腹腔内治疗后15个月的安全性和有效性数据
Presenter:Stein G Larsen，PhD|Norwegian Radium Hospital
Abstract:3519|Poster Bd#:219
Neoadjuvant chemotherapy(NAC)followed by total mesorectal excision(TME)and adjuvant chemotherapy versus TME followed by adjuvant chemotherapy in very low-lying clinical(c)T3 rectal cancer(NAIR):A multicenter，randomized，open-label，phase 2/3 trial.
新辅助化疗（NAC）后全肠系膜切除（TME）和辅助化疗vs.TME后辅助化疗治疗极低部位临床分期T3直肠癌：多中心、随机、开放、Ⅱ/Ⅲ期NAIR试验
Presenter:Yuichiro Tsukada，MD，PhD|Department of Colorectal Surgery，National Cancer Center Hospital East
Abstract:3520|Poster Bd#:220
Sustained organ preservation in rectal cancer patients treated with total neoadjuvant therapy:Long-term results of the OPRA trial.
全程新辅助治疗直肠癌患者持续器官保留：OPRA试验的长期结果
Presenter:Floris S Verheij，BSc|Memorial Sloan Kettering Cancer Center
Abstract:3521|Poster Bd#:221
Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer:Updated results from GALAXY study in the CIRCULATE-Japan.
循环肿瘤DNA动力学作为根治性切除的结直肠癌患者复发的早期预测因子：来自CIRCULATE-Japan平台GALAXY研究的更新结果
Presenter:Eiji Oki，MD，PhD，FACS|Kyushu University
Abstract:3522|Poster Bd#:222
Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer(CRC):Results from the MD Anderson INTERCEPT program.
结直肠癌（CRC）监测期间基于ctDNA阳性的微小残留病检测与未确诊的伴随放射学复发的相关性：来自MD安德森INTERCEPT项目的结果
Presenter:Arvind Dasari，MD，MS|Department of Gastrointestinal Medical Oncology，The University of Texas MD Anderson Cancer Center
Abstract:3523|Poster Bd#:223
Predictive models of recurrence from transcriptomic signatures of the tumor microenvironment and cell cycle in stage III colon cancer from PETACC-8 and IDEA France trials.
来自PETACC-8和IDEA法国试验的Ⅲ期结肠癌肿瘤微环境和细胞周期转录组特征的复发预测模型
Presenter:Claire Gallois，MD|Institut du Cancer Paris CARPEM，APHP，Digestive Oncology Department，APHP.Centre-UniversitéParis Cité，Hôpital Européeen G.Pompidou
京公网安备 11010502033352号